Dario Trapani

9.3k total citations · 4 hit papers
201 papers, 4.3k citations indexed

About

Dario Trapani is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Dario Trapani has authored 201 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Oncology, 63 papers in Pulmonary and Respiratory Medicine and 50 papers in Cancer Research. Recurrent topics in Dario Trapani's work include Economic and Financial Impacts of Cancer (36 papers), Cancer Immunotherapy and Biomarkers (33 papers) and Health Systems, Economic Evaluations, Quality of Life (30 papers). Dario Trapani is often cited by papers focused on Economic and Financial Impacts of Cancer (36 papers), Cancer Immunotherapy and Biomarkers (33 papers) and Health Systems, Economic Evaluations, Quality of Life (30 papers). Dario Trapani collaborates with scholars based in Italy, United States and United Kingdom. Dario Trapani's co-authors include Giuseppe Curigliano, Giulia Viale, Carmen Criscitiello, Antonio Marra, Paolo Tarantino, Paolo D’Amico, Bruno A. Duso, Carmen Belli, André Ilbawi and Emanuela Ferraro and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Dario Trapani

179 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HER2-Low Breast Cancer: Pathological and Clinical Landscape

2020 490 citations Paolo Tarantino, Sara M. Tolaney et al. Journal of Clinical Oncology profile →
Targeting the microenvironment in solid tumors

2018 385 citations Carmen Belli, Dario Trapani et al. profile →
Global challenges and policy solutions in breast cancer control

2022 172 citations Dario Trapani, André Ilbawi et al. profile →
Evolution of low HER2 expression between early and advanced-stage breast cancer

2022 121 citations Paolo Tarantino, Eleonora Nicolò et al. European Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dario Trapani Italy	31	2.2k	1.2k	977	921	598	201	4.3k
Julia A. Beaver United States	39	2.7k 1.2×	1.5k 1.3×	1.1k 1.1×	1.1k 1.2×	432 0.7×	131	4.8k
Paul G. Kluetz United States	34	1.8k 0.8×	1.3k 1.1×	608 0.6×	579 0.6×	565 0.9×	174	4.0k
Shenghui Tang United States	39	2.9k 1.3×	1.8k 1.5×	855 0.9×	1.2k 1.3×	713 1.2×	116	5.3k
Gilberto Lopes United States	35	2.2k 1.0×	1.5k 1.2×	607 0.6×	538 0.6×	352 0.6×	221	3.7k
Joseph Gligorov France	36	2.8k 1.2×	966 0.8×	1.3k 1.3×	859 0.9×	616 1.0×	284	4.5k
Debra A. Patt United States	33	4.6k 2.0×	1.8k 1.5×	1.3k 1.3×	1.2k 1.3×	735 1.2×	122	6.2k
Matteo Lambertini Italy	46	4.1k 1.8×	1.1k 0.9×	1.3k 1.4×	1.1k 1.2×	403 0.7×	330	7.3k
Shailendra Verma Canada	33	2.7k 1.2×	1.3k 1.1×	846 0.9×	781 0.8×	553 0.9×	177	4.8k
Mourad Tighiouart United States	38	1.7k 0.8×	930 0.8×	700 0.7×	1.6k 1.8×	311 0.5×	152	5.0k
Narjust Duma United States	18	1.6k 0.7×	1.2k 1.0×	594 0.6×	809 0.9×	240 0.4×	95	3.3k

Countries citing papers authored by Dario Trapani

Since Specialization

Citations

This map shows the geographic impact of Dario Trapani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dario Trapani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dario Trapani more than expected).

Fields of papers citing papers by Dario Trapani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dario Trapani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dario Trapani. The network helps show where Dario Trapani may publish in the future.

Co-authorship network of co-authors of Dario Trapani

This figure shows the co-authorship network connecting the top 25 collaborators of Dario Trapani. A scholar is included among the top collaborators of Dario Trapani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dario Trapani. Dario Trapani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Izzo, Domenico, et al.. (2025). Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy. Therapeutic Advances in Medical Oncology. 17. 12754197–12754197. 14 indexed citations

Venetis, Konstantinos, Chiara Frascarelli, Luca Boscolo Bielo, et al.. (2025). Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact. European Journal of Cancer. 217. 115233–115233. 9 indexed citations

Šeparović, Robert, et al.. (2024). Globalization of clinical research in oncology: Status, challenges, and future directions. Journal of Cancer Policy. 42. 100500–100500. 3 indexed citations

Valenza, Carmine, Eleonora Nicolò, Dario Trapani, et al.. (2024). Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study. The Oncologist. 30(7). 1 indexed citations

Ascione, Liliana, et al.. (2024). Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates. American Society of Clinical Oncology Educational Book. 44(3). e431766–e431766. 24 indexed citations

Valenza, Carmine, Dario Trapani, Sibylle Loibl, et al.. (2024). Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response. Journal of Clinical Oncology. 42(20). 2372–2376. 2 indexed citations

Trapani, Dario, et al.. (2024). As bleak as it sounds? Analysing trends in oncology clinical trial initiation in the UK from 2010 to 2022. SHILAP Revista de lepidopterología. 3(1). e000410–e000410. 1 indexed citations

Michaeli, Julia Caroline, Thomas Michaeli, Dario Trapani, et al.. (2024). Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price. Breast Cancer. 31(6). 1144–1155. 2 indexed citations

Antonarelli, Gabriele, Chiara Corti, Paolo Tarantino, et al.. (2023). Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure. ESMO Open. 8(4). 101608–101608. 21 indexed citations

10.

Piggott, Thomas, Lorenzo Moja, Kristina Jenei, et al.. (2023). GRADE Concept 7: Issues and Insights Linking Guideline Recommendations to Trustworthy Essential Medicine Lists. Journal of Clinical Epidemiology. 166. 111241–111241. 4 indexed citations

11.

Roitberg, Felipe, Teresa Amaral, Nathan I. Cherny, et al.. (2023). Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain. ESMO Open. 8(5). 101617–101617.

12.

Valenza, Carmine, et al.. (2023). Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment. Cancers. 15(3). 767–767. 42 indexed citations

13.

Denburg, Avram, Adam Fundytus, Muhammad Saghir Khan, et al.. (2022). Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey. JCO Global Oncology. 8(8). e2200034–e2200034. 8 indexed citations

14.

Seeber, Andreas, et al.. (2022). FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?. Life. 12(1). 81–81. 19 indexed citations

15.

Trapani, Dario, et al.. (2021). The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: The ONCOLLEGE-001 survey. Journal of Cancer Policy. 28. 100285–100285. 9 indexed citations

16.

Khan, Shah Zeb, et al.. (2020). Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine. SHILAP Revista de lepidopterología. 3(1). 1–22. 5 indexed citations

17.

Willenbacher, Ella, Shah Zeb Khan, Dario Trapani, et al.. (2019). Curcumin: New Insights into an Ancient Ingredient against Cancer. International Journal of Molecular Sciences. 20(8). 1808–1808. 121 indexed citations

18.

Trapani, Dario, et al.. (2019). The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas. Current Drug Targets. 21(10). 946–961. 17 indexed citations

19.

Belli, Carmen, Massimo Zuin, Luca Mazzarella, et al.. (2018). Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. Critical Reviews in Oncology/Hematology. 132. 125–129. 21 indexed citations

20.

Rampoldi, Antonio, Silvia Secco, Antonio Galfano, et al.. (2017). Prostatic Artery Embolization as an Alternative to Indwelling Bladder Catheterization to Manage Benign Prostatic Hyperplasia in Poor Surgical Candidates. CardioVascular and Interventional Radiology. 40(4). 530–536. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact